http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IT-1166627-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f2e77c802d54a2eed86938295e5ac96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51134f5babb1a9ea324495af448ea39d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- |
| filingDate | 1979-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1987-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1987-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IT-1166627-B |
| titleOfInvention | USE OF 2- (2-TENOILTIO) -PROPIONYLGLYCIN AS A MUCOLYTIC AND ANTIBRONCOSPASTIC AGENT |
| abstract | 2-(2-Thenoylthi)propionylglycine of formula (I) and its salts e.g. sodium are new. Used treatment of chronic and acute hepatopathy and realted toxicity problems. (I) also have mucolytic and antibronchospasmodic activity and may be used to treat acute respiratory tract infections associated with bronchial hypersecretion, mucovisadotic syndromes etc. (I) may be administered by oral, rectal, parenteral or inhalation etc. (I) is compared with 2-mercaptopropionyl-glycine (II). (I) is much more stable and does not give rise to undesirable odour and taste as does (II). Toxicity, pharmacological and clinical tests are described e.g. oral LD50 in rats and mice is 2500mg/kg, i.v. LD50 in mice is 1250mg/kg. and intramuscular LD50 in rats is 1801mg/kg. |
| priorityDate | 1979-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.